Successful treatment with adalimumab in a familial case of gastrointestinal Behcet's disease

Journal of Crohn's and Colitis

Volumn 5, Issue 4, 2011, Pages 364-368

  De Cassan, Chiara ^a   De Vroey, Bénédicte ^a   Dussault, Catherine ^a   Hachulla, Eric ^a   Buche, Sebastien ^a   Colombel, Jean Frédéric ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Adalimumab; Beh et's disease; Familial aggregation; Gastrointestinal localisation

Indexed keywords

ADALIMUMAB; COLCHICINE; DAPSONE; INFLIXIMAB; PENTOXIFYLLINE; PREDNISONE; STEROID;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; CASE REPORT; COLONOSCOPY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENITAL ULCER; HUMAN; HUMAN TISSUE; ILEUM; LONG TERM CARE; MALE; MOUTH ULCER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; YOUNG ADULT;

EID: 79958862562     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.03.006     Document Type: Article

References (39)

1. Criteria for diagnosis of Behçet's disease. Lancet 1990, 335:1078-1080. International Study Group for Behçet's Disease.
2. Sakane T., Takeno M., Suzuki N., Inaba G. Behçet's disease. N Engl J Med 1999, 341(17):1284-1291.
3. Ebert E.C. Gastrointestinal manifestations of Behçet's disease. Dig Dis Sci 2009, 54(2):201-207.
4. Verity D.H., Wallace G.R., Vaughan R.W., Kondeatis E., Madanat W., Zureikat H., et al. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999, 54(3):264-272.
5. Palamaras I., El-Jabbour J., Pietropaolo N., Thomson P., Mann S., Robles W., et al. Metastatic Crohn's disease: a review. J Eur Acad Dermatol Venereol 2008, 22(9):1033-1043.
6. Fresko I., Ugurlu S., Ozbakir F., Celik A., Yurdakul S., Hamuryudan V., et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet's syndrome. Clin Exp Rheumatol 2005, 23(4 Suppl. 38):S67-S70.
7. Papp M., Norman G.L., Altorjay I., Lakatos P.L. Utility of serological markers in inflammatory bowel diseases: gadget or magic?. World J Gastroenterol 2007, 13(14):2028-2036.
8. D'Haens G.R., Panaccione R., Higgins P.D., Vermeire S., Gassull M., Chowers Y., et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response. Am J Gastroenterol 2010, published online November 2. 10.1038/ajg.2010.392.
9. Sfikakis P.P., Markomichelakis N., Alpsoy E., Assaad-Khalil S., Bodaghi B., Gul A., et al. Anti-TNF therapy in the management of Behcet's disease - review and basis for recommendations. Rheumatology (Oxford) 2007, 46(5):736-741.
10. Evaluation of the international criteria for Behcet's disease (ICBD). Clin Exp Rheumatol 2006, 24(Suppl. 42):S13. International Team for the Revision of the International Criteria for Behcet's Disease.
11. International Team for the Revision of the International Criteria for Behcet's Disease Revision of the international criteria for Behcet's disease (ICBD). Clin Exp Rheumatol 2006, 24(Suppl. 42):S14-S15.
12. Davatchi F., Sadeghi Abdollahi B., Shahram F., Nadji A., Chams-Davatchi C., Shams H., et al. Validation of the International Criteria for Behçet's disease (ICBD) in Iran. Int J Rheum Dis 2010, 13(1):55-60.
13. Bawazeer A., Raffa L.H. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 2010, 18(3):226-232.
14. Lee S.W., Lee S.Y., Kim K.N., Jung J.K., Chung W.T. Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report. Clin Rheumatol 2010, 29(1):91-93.
15. Callejas-Rubio J.L., Sánchez-Cano D., Ríos-Férnandez R., Ortego-Centeno N. Treatment of Behçet's disease with adalimumab. Med Clin (Barc) 2008, 131(11):438-439. Spanish.
16. Sànchez-Cano D., Callejas-Rubio J.L., Ortego-Centeno N., Ruiz-Villaverde R. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab. Clin Exp Rheumatol 2006, 24(5 Suppl. 42):S128.
17. Leccese P., D'Angelo S., Angela P., Coniglio G., Olivieri I. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab. Clin Exp Rheumatol 2010, 28(4 Suppl. 60):S102.
18. Atzeni F., Leccese P., D'Angelo S., Sarzi-Puttini P., Olivieri I. Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab. Clin Exp Rheumatol 2010, 28(4 Suppl. 60):S94.
19. Olivieri I., D' Angelo S., Padula A., Leccese P., Mennillo G.A. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept. Clin Exp Rheumatol 2009, 27(2 Suppl. 53):S112.
20. Takase K., Ohno S., Ideguchi H., Uchio E., Takeno M., Ishigatsubo Y. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis. Rheumatol Int Oct 9, 2009.
21. Belzunegui J., López L., Paniagua I., Intxausti J.J., Maíz O. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease. Clin Exp Rheumatol 2008, 26(4 Suppl. 50):S133-S134.
22. van Laar J.A., Missotten T., van Daele P.L., Jamnitski A., Baarsma G.S., van Hagen P.M. Adalimumab: a new modality for Behçet's disease?. Ann Rheum Dis 2007, 66(4):565-566.
23. Mushtaq B., Saeed T., Situnayake R.D., Murray P.I. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 2007, 21(6):824-825.
24. Kim E.S., Chung W.C., Lee K.M., Lee B.I., Choi H., Han S.W., et al. A case of intestinal Behçet's disease similar to Crohn's colitis. J Korean Med Sci 2007, 22(5):918-922.
25. Pay S., Simşek I., Erdem H., Dinç A. Immunopathogenesis of Behçet's disease with special emphasize to the possible role of antigen presenting cells. Rheumatol Int 2007, 27(5):417-424.
26. Cobrin G.M., Abreu M.T. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 2005, 206:277-295.
27. Naganuma M., Iwao Y., Kashiwagi K., Funakoshi S., Ishii H., Hibi T. A case of Behcet's disease accompanied by colitis with longitudinal ulcers and granuloma. J Gastroenterol Hepatol 2002, 17(1):105-108.
28. Houman H., Ben Dahmen F., Ben Ghorbel I., Chouaib S., Lamloum M., Kchir N., et al. Behçet's disease associated with Crohn's disease. Ann Med Interne (Paris) 2001, 152(7):480-482. French.
29. Tolia V., Abdullah A., Thirumoorthi M.C., Chang C.H. A case of Behcet's disease with intestinal involvement due to Crohn's disease. Am J Gastroenterol 1989, 84:322-325.
30. Chamberlain M.A. Behcet's syndrome in 32 patients in Yorkshire. Ann Rheum Dis 1977, 36(6):491-499.
31. Al-Otaibi L.M., Porter S.R., Poate T.W. Behçet's disease: a review. J Dent Res 2005, 84(3):209-222.
32. Azizlerli G., Köse A.A., Sarica R., Gül A., Tutkun I.T., Kulaç M., et al. Prevalence of Behcet's disease in Istanbul, Turkey. Int J Dermatol 2003, 42(10):803-806.
33. Tunc R., Keyman E., Melikoglu M., Fresko I., Yazici H. Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. J Rheumatol 2002, 29(11):2393-2396.
34. Monselise A., Weinberger A., Monselise Y., Fraser A., Sulkes J., Krause I. Anti-Saccharomyces cerevisiae antibodies in Behçet's disease - a familial study. Clin Exp Rheumatol 2006, 24(5 Suppl. 42):S87-S90.
35. Rhee S.H., Kim Y.B., Lee E.S. Comparison of Behcet's disease and recurrent aphthous ulcer according to characteristics of gastrointestinal symptoms. Korean Med Sci 2005, 20(6):971-976.
36. Gül A., Inanç M., Ocal L., Aral O., Koniçe M. Familial aggregation of Behçet's disease in Turkey. Ann Rheum Dis 2000, 59(8):622-625.
37. Meguro A., Inoko H., Ota M., Katsuyama Y., Oka A., Okada E., et al. Genetics of Behçet disease inside and outside the MHC. Ann Rheum Dis 2010, 69(4):747-754.
38. Yazici H., Fresko I., Yurdakul S. Behçet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol 2007, 3(3):148-155.
39. Kurata R., Nakaoka H., Tajima A., Hosomichi K., Shiina T., Meguro A., et al. TRIM39 and RNF39 are associated with Behçet's disease independently of HLA-B51 and -A26. Biochem Biophys Res Commun 2010, 401(4):533-537.